Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
CES Medicina
Print version ISSN 0120-8705
Abstract
ROJAS-HENAO, Natalia Andrea and GRANADOS-VEGA, Elkyn Johan. Glucagon like peptide 1 receptor agonists: a therapy for diabetes management. CES Med. [online]. 2018, vol.32, n.1, pp.23-30. ISSN 0120-8705. https://doi.org/10.21615/cesmedicina.32.1.3.
Introduction:
Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Methods:
A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor, Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release.
Results:
The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes.
Conclusions:
GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety.
Keywords : Diabetes Mellitus, Type 2; Glucagon-like peptide-1, Hypoglycemia, Hemoglobin A, glycosylated.